研究疾病:
|
乳腺癌
|
研究疾病代码:
|
|
Target disease:
|
Breast Cancer
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
其它
Others
|
研究目的:
|
1.观察基于“肝肾同源”理论的益肾调肝方对乳腺癌术后患者AIMSS的临床疗效并评价其安全性。
2.通过本研究的开展,对所有内分泌治疗患者骨代谢、性激素、生长激素等实验室指标进行动态观察,建立分析模型,筛选出适宜的临床靶标,为早期防治提供基础。
|
Objectives of Study:
|
1. To observe the clinical efficacy of Yishen Tiaogan prescription based on the theory of "liver and kidney homology" for AIMSS patients after breast cancer surgery and evaluate its safety.
2. Through the development of this study, dynamic observation of laboratory indicators such as bone metabolism, sex hormone and growth hormone in all patients undergoing endocrine therapy was conducted to establish an analysis model and screen out suitable clinical targets, providing a basis for early prevention and treatment.
|
药物成份或治疗方案详述:
|
本项目为优效性研究,入组患者均采用口服中药干预。
对照组:乳癌术后方加减干预。
试验组:乳癌术后方加减+益肾调肝方干预。
用法用量:水煎 400ml,日一剂,分早晚两次餐后一小时温服。
治疗及随访时间:中药治疗3个月为一疗程,本研究观察2个疗程的临床疗效。
|
Description for medicine or protocol of treatment in detail:
|
This study was of excellent efficacy, and all patients were treated with oral Chinese medicine intervention.
Control group: Add and subtract Ruaishuhou prescription
Experimental group: Add and subtract Ruaishuhou prescription and Yishentiaogan prescription
Usage and Dosage: decocted 400ml in water, one dose per day, taken twice in the morning and evening, one hour after meals.
Treatment and follow-up time: Chinese medicine treatment for 3 months as a course, this study to observe the clinical efficacy of 2 courses.
|
纳入标准:
|
1.年龄在18~65岁;
2.经病理学诊断为乳腺癌,免疫组化诊断为HR阳性的患者;
3.已完成手术、化疗、放疗,和/或靶向治疗;
4.已接受AIs(阿那曲唑、来曲唑、依西美坦)至少2个月;
5.中医辨证属于肝肾亏虚(症见腰膝酸软,关节僵硬,头晕目眩等);
6.KPS评分≥60分;
7.预计生存期超过6个月;
8.签署知情同意书,自愿接受本研究治疗方案。
|
Inclusion criteria
|
1. Aged between 18 and 65;
2. Patients diagnosed as breast cancer by pathology and HR positive by immunohistochemistry;
3. Completed surgery, chemotherapy, radiotherapy, and/or targeted therapy;
4. Have received AIs (anastrozole, Letrozole, exemestane) for at least 2 months;
5. TCM syndrome differentiation belongs to liver and kidney deficiency (symptoms include tenderness of waist and knee, stiffness of joints, dizziness, etc.);
6.KPS score ≥60;
7. The expected survival is more than 6 months;
8. Signed the informed consent and voluntarily accepted the treatment plan of the study.
|
排除标准:
|
1.骨矿疾病:如甲状旁腺功能减退症或亢进症、畸形性骨炎、成骨不全、骨软化症等;
2.影响骨代谢的疾病:如库欣综合征、甲状腺功能亢进症、风湿或类风湿性关节炎等;
3.研究前应用类固醇类激素或抗惊厥药物>6个月;
4.6个月内曾使用激素替代治疗:如糖皮质激素、甲状旁腺激素、雌激素等;
5.6个月内曾进行过四肢关节相关手术治疗;
6.合并有心血管、肝、肾和造血系统等严重原发性疾病;
7.研究过程中出现明显的病情进展及远处转移者;
8.认知能力丧失或精神异常的精神病患者。
|
Exclusion criteria:
|
1. Bone mineral diseases: such as hypoparathyroidism or hyperthyroidism, malformed osteitis, osteogenesis imperfection, osteomalacia, etc.;
2. Diseases that affect bone metabolism, such as Cushing's syndrome, hyperthyroidism, rheumatism or rheumatoid arthritis;
3. Steroid hormones or anticonvulsants were used for more than 6 months before the study;
4. Used hormone replacement therapy within 6 months, such as glucocorticoid, parathyroid hormone, estrogen, etc.;
5. Had surgery related to extremities within 6 months;
6. Complicated with serious primary diseases of cardiovascular, liver, kidney and hematopoietic systems;
7. Patients with obvious disease progression and distant metastasis during the study;
8. Psychopaths with cognitive impairment or mental abnormalities.
|
研究实施时间:
Study execute time:
|
从From
2021-10-01
至To
2024-09-30
|
征募观察对象时间:
Recruiting time:
|
从From
2022-03-22
至To
2023-06-30
|